Lenalidomide

Indications

Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone (1.1). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) (1.1). • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities (1.2). • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (1.3). • Previously treated follicular lymphoma (FL), in combination with a rituximab product (1.4). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product (1.5). Limitations of Use: • Lenalidomide capsules are not indicated and are not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials (1.4).